Patritumab帕曲妥单抗帕曲妥单抗,1262787-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Patritumab

CAS No. : 1262787-83-6

MCE 国际站：Patritumab

产品活性：Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用，可有效抑制 EGFR，HER2，HER3，ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis)，也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK  |  PI3K/Akt/mTOR  |  Stem Cell/Wnt  |  MAPK/ERK Pathway  |  Cell Cycle/DNA Damage  |  Epigenetics  |  Apoptosis

作用靶点：EGFR  |  Akt  |  ERK  |  PARP  |  Survivin

In Vitro: Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.

In Vivo: Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.

相关产品：Olaparib  |  Deferoxamine mesylate  |  Osimertinib  |  MK-2206 dihydrochloride  |  Trastuzumab  |  PD98059  |  Gefitinib  |  Cetuximab  |  SC79  |  XAV-939  |  Talazoparib  |  Erlotinib  |  Niraparib  |  Yoda 1  |  Afatinib  |  Capivasertib  |  SCH772984  |  TBHQ  |  Lapatinib  |  Saruparib  |  AG490  |  Tauroursodeoxycholate  |  Ipatasertib  |  Trastuzumab deruxtecan  |  Genistein  |  Rucaparib  |  Neratinib  |  Veliparib  |  Tucatinib  |  Ulixertinib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds